All News

Veyonda, a novel proprietary formulation of idronoxil, is a first-in-class, dual-acting oncotoxic and immuno-oncology molecule.

New validated testing method for multiple sclerosis measures kappa immunoglobulin free light chains in cerebrospinal fluid.

Namzaric is indicated for the treatment of moderate to severe dementia related to Alzheimer disease.

Benefiber is a plant-based prebiotic fiber supplement that supports digestive health.

Despite their lower antibody responses, patients who are vaccinated receive protection from SARS-CoV-2 infection and severe disease.

Mindfulness-based cognitive therapy helps change feelings and thoughts about experiences, minimizing depressive episodes, analysis indicates.

Analysis to be presented at the American College of Cardiology’s 71st Annual Scientific Session is based on the health records of 495,386 patients.

Elizabeth Spurlock, MA, PHR, director of HR Business Partner at Texas Oncology, discusses how burnout among physicians, nurses, and hospital administrators has impacted the role of the pharmacist in patient care.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

The drug met the co-primary endpoints of clinical remission at both weeks 12 and 52 and all key secondary endpoints in the study.

Patient treatment improves and medication prices decline as a result, a new analysis indicates.

Pharmacy Times spoke with students at the Idaho State University College of Pharmacy and its partner program at the University of Alaska Anchorage College of Health.

Fourth-year student Ashley Lam discussed how pharmacists and pharmacy students can get involved in environmental issues.

Semaglutide (Ozempic; Novo Nordisk) approved as a once-weekly subcutaneous injection for the treatment of adults with type 2 diabetes.

FDA approves the EVO/EVO+ Visian Implantable Collamer Lens for the correction of myopia and myopia with astigmatism.

RBX2660, a standardized, stabilized, novel microbiota-based live therapeutic, shows promise treating patients with recurrent Clostridium difficile infection.

Ibalizumab-uiyk (Trogarzo) is a CD4-directed post-attachment HIV-1 inhibitor.

Daily Fiber SF is used for digestive support and for stomach regularity.

The monotherapy demonstrates rapidly improved symptoms over 4 weeks for individuals with moderate-to-severe disease.

Abemaciclib (Verzenio; Lilly) is the first addition to adjuvant endocrine therapy approved by the FDA in two decades.

Johnson & Johnson’s Janssen Pharmaceutical Companies subsidiary’s post-hoc analysis of Tremfya demonstrates clinically significant improvements.

Study finds that the use of biologics and other potentially immunocompromising therapies for atopic dermatitis was associated with low risk of severe COVID-19.

Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.

Prurigo nodularis causes intense, persistent itch, with thick skin nodules that can cover most of the body.

Curtailing the availability of meth precursors in the principal focus of the law, paving the way for states to follow suit.

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

Baricitinib (Olumiant; Eli Lilly and Incyte ) was found to produce significant hair regrowth on the scalp, eyelashes, and eyebrows of adults with severe alopecia areata.

Electronic, open loop, clinical decision support system helped to produce a 38% lower overall mortality rate among patients with pneumonia.

Trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant) is a HER2/neu receptor antagonist indicated for early and advanced breast cancer, advanced stomach cancer, and gastroesophageal junction cancer.